Tony Jarkowski

Tony Jarkowski

Company: Bristol Myers- Squibb

Job title: Executive Director, Early Development Program Lead

Seminars:

Panel Discussion: Predicting Future Directions for NSCLC Therapeutic Development and Treatment 4:00 pm

How will future combinations, or novel therapeutic design (bispecifics etc), address acquired resistance to TKI treatments and improve patient outcomes? How will new, fast and accurate diagnostic technologies enable appropriate patient selection for future clinical investigations and increase the clinical utility of new approved therapies? What is on the horizon for targeted therapies for uncommon…Read more

day: Day Two

Is Now the Critical Tipping Point for Progress with Immunotherapy in Resectable NSCLC? Where Are We Now and What’s to Come in 2021 and Beyond? 8:30 am

Review historical data along with current approaches for potentially resectable NSCLC Discuss drug development in NSCLC and why progress in resectable NSCLC has lagged behind advanced stages of disease Describe emerging data, science, and future opportunities for immunotherapy to improve outcomes within resectable NSCLC, including the neoadjuvant, adjuvant and peri-adjuvant settingsRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.